Skip to content
BHP

Selank dosing — research reference

Pre-clinical dose ranges and routes

Reviewed by the BestHealingPeptides Editorial Team ·

This page summarises the pre-clinical research dose ranges reported in the published literature for Selank. The ranges shown are derived from rodent and other animal model studies and do not constitute a recommendation for human use. Selank is not licensed as a medicine in the United Kingdom and may not be administered to humans outside an authorised clinical trial.

When interpreting the ranges below, three considerations dominate. First, dose conversion across species is not linear in either body weight or surface area for peptides; allometric scaling from rodent doses to human equivalents introduces substantial uncertainty. Second, route of administration materially affects pharmacokinetic exposure — subcutaneous, intraperitoneal, intramuscular, and oral routes have different bioavailability profiles for the same molecule. Third, batch-to-batch variability in research-chemical-grade peptide preparations means that nominal doses do not always correspond to actual delivered active peptide; Certificate of Analysis verification of HPLC purity and identity is essential before any in-vivo work.

For full mechanistic context, study summaries, and safety information, see the main Selank research profile.

Reported routes of administration

  • Intranasal (standard research and clinical route)
  • Subcutaneous injection (pre-clinical research)

Reported half-life

Very short plasma half-life (~minutes) due to rapid peptidase degradation; functional pharmacology dominated by intranasal delivery achieving direct CNS access. Functional anxiolytic and modest cognitive effects from a single intranasal dose persist for 4-12 hours, longer than Semax effects despite similar plasma half-life — attributed to downstream effects on enkephalin and monoamine system tone that persist beyond peptide presence.

See the dedicated half-life reference page for fuller pharmacokinetic context.

Reported pre-clinical dose ranges

Reported Selank research-model dose ranges
ModelRouteReported rangeNote
Russian clinical anxiolytic use (0.15% nasal drops)Intranasal75-450 µg/day divided 2-3 times dailyStandard Russian-marketed dosing for generalised anxiety disorder. Not a validated UK clinical recommendation.
Pre-clinical rodent intranasal protocolsIntranasal100-1000 µg/kg/dayStandard pre-clinical research dosing for anxiety, cognitive, and immunomodulatory endpoint studies.
Research-chemical-community intranasal protocolsIntranasal150-900 µg/day dividedVariable use; not a validated human dosing recommendation.
Ranges reported in pre-clinical literature. For laboratory and research use only.

Practical research considerations

Selecting a research dose for Selank should account for the route used in the source publication, the species and strain of the animal model, the experimental endpoint timepoint, and any vehicle effects. A common methodological error is to apply a rodent intraperitoneal dose to a subcutaneous protocol without route-correction, which materially over- or under-estimates exposure. For new research programmes, pilot dose-ranging studies with serial endpoint sampling are advised before committing to a single dose tier.

Reconstitution vehicle is a recurring source of inter-study variability. Bacteriostatic water with 0.9% benzyl alcohol is the standard research vehicle; sterile water for injection is the alternative where benzyl alcohol interferes with downstream assays. See the reconstitution reference page and the reconstitution master guide for protocol-level detail.

For safety considerations, contraindications, and known formulation interactions, see the safety reference page.

Where to source Selank for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.